New insider activity at Beam Therapeutics ( (BEAM) ) has taken place on October 29, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a recent transaction, Fmr Llc divested 459 shares of Beam Therapeutics, amounting to a total sale value of $12,246. This move reflects a strategic decision in their investment portfolio involving Beam Therapeutics stock.
Recent Updates on BEAM stock
Beam Therapeutics has recently seen significant developments in its clinical trials and stock performance. The company announced updates on several key studies, including the BEAM-302 study for Alpha-1 Antitrypsin Deficiency (AATD), the BEAM-301 study for Glycogen Storage Disease Type Ia (GSDIa), and the BEACON trial for sickle cell disease. These trials are crucial as they aim to address rare genetic disorders, potentially positioning Beam Therapeutics as a leader in the gene-editing space. Jefferies initiated coverage with a positive outlook, citing BEAM-302’s potential as a one-time therapy for AATD, estimating significant peak sales. This optimism is tempered by a modest valuation of the BEAM-101 program for sickle cell disease, but a key near-term catalyst is anticipated. The market is closely watching these developments, with significant implications for Beam’s stock performance and investor confidence.
Spark’s Take on BEAM Stock
According to Spark, TipRanks’ AI Analyst, BEAM is a Neutral.
Beam Therapeutics’ overall stock score is primarily impacted by its financial performance challenges, including declining revenues and negative cash flows. While technical analysis shows positive momentum, the valuation remains unattractive due to negative earnings. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on BEAM stock, click here.
More about Beam Therapeutics
YTD Price Performance: 7.00%
Average Trading Volume: 2,655,683
Technical Sentiment Signal: Buy
Current Market Cap: $2.67B